Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Minimal residual disease

J Radich1

  • 1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.

Current Opinion in Hematology
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Minimal residual disease detection, aided by polymerase chain reaction, shows varied relapse prediction across cancers. Further studies are needed to clarify its clinical significance in different hematologic malignancies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale.

Leukemia·2016
Same author

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.

Leukemia·2009
Same author

BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features.

Leukemia·2008
Same author

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia.

Leukemia·2006
Same author

Acute myeloid leukemia.

Hematology. American Society of Hematology. Education Program·2001
Same author

Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.

Annals of the New York Academy of Sciences·2001
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Technological advancements like polymerase chain reaction (PCR) have significantly enhanced the study of minimal residual disease (MRD).
  • Identification of genetic lesions in human malignancies provides targets for MRD detection.
  • Advances in gene identification, cloning, and PCR amplification have outpaced clinical validation of MRD's significance.

Purpose of the Study:

  • To evaluate the clinical significance and predictive value of minimal residual disease detection in various human malignancies.
  • To determine if the mere presence of MRD accurately foretells relapse.
  • To highlight the need for controlled studies to assess MRD's prognostic implications.

Main Methods:

  • Utilizing polymerase chain reaction (PCR) technology for the detection of minimal residual disease.

Related Experiment Videos

  • Analyzing genetic lesions specific to different human malignancies.
  • Reviewing existing clinical data on MRD detection and patient relapse rates.

    • Main Results:

    • The detection of MRD does not universally predict relapse.
    • MRD presence is associated with a high relapse risk in acute lymphoblastic leukemia and acute prolymphocytic leukemia.
    • MRD presence in t(8;21) acute myeloid leukemia, chronic myeloid leukemia, and t(14;18) non-Hodgkin's lymphoma is not clearly linked to impending relapse.

    Conclusions:

    • The predictive value of MRD varies significantly depending on the specific malignancy.
    • Carefully controlled clinical studies are essential to accurately evaluate the prognostic significance of MRD.
    • Further research is required to establish standardized MRD assessment protocols and their clinical utility.